In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Clinical Trials (PDQ®)

Laser Ablation After Stereotactic Radiosurgery

Basic Trial Information
Trial Description
     Summary
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
No phase specifiedSupportive care, TreatmentActiveOver 18Pharmaceutical / IndustryLAASR
NCT01651078

Trial Description

Summary

The need for new technologies and devices in the field of neurosurgery is well established. In April 2013, FDA cleared NeuroBlate™ System, minimally invasive robotic laser thermotherapy tool. It employs a pulsed surgical laser to deliver targeted energy to abnormal brain tissue caused by tumors and lesions. This post-marketing, multi-center study will include patients with metastatic tumors who failed stereotactic radiosurgery and are already scheduled for NeuroBlate procedure. The study will collect clinical outcome, Quality of Life (QoL) and, where feasible, healthcare utilization data for publication.

Eligibility Criteria

Key Inclusion Criteria:

1. Patient has signed and received a copy of the Informed Consent Form

2. Patient may have up to 3 target supratentorial metastatic lesions previously treated with stereotactic radiosurgery, with radiological evidence of progression, pseudoprogression or radionecrosis. Subject may have additional non target lesions present as long as they are not expected (in Investigator's judgment) to contribute to symptomatology during the course of the study or confound interpretation of radiological and clinical measures.

3. Karnofsky Performance Status (KPS) ≥ 60.

Key Exclusion Criteria:

1. Females who are pregnant, breast feeding, or plan to become pregnant in the 6 months following index procedure.

2. Leptomeningeal metastases.

3. Uncontrolled infectious process.

4. Uncontrolled hypertension (systolic >180 mm Hg), angina pectoris, or cardiac dysrhythmia, or recent (within 6 weeks) history of intracranial hemorrhage.

5. Serious infection, immunosuppression or concurrent medical condition (chronic or acute in nature) that may prevent safe participation or ability to meet follow-up requirements.

6. Abnormal absolute neutrophil count (ANC<1000/mm), platelets (<100,000/mm) or the administration of antiplatelet agents (aspirin, plavix etc) or anticoagulation within 7 days prior to treatment.

7. Inadequate bone marrow, liver and renal function (e.g., total bilirubin > 1.5 x ULN; AST, ALT > 2.5 x ULN; alkaline phosphatase > 2.5 x ULN; serum creatinine > 1.5 x ULN).

Trial Contact Information

Trial Lead Organizations/Sponsors

Monteris Medical, Incorporated (US)

Veronica Chiang, MDPrincipal Investigator

Trial Sites

U.S.A.
Connecticut
  New Haven
 Yale Cancer Center
 Judith Hess Ph: 203-737-6259
  Email: Judith.Hess@yale.edu
 Veronica Chiang, MDPrincipal Investigator
Missouri
  St. Louis
 Washington University in St Louis
 Eileen Jacobs, R.T.(R)(M) Ph: 314-362-4110
  Email: Jacobse@mir.wustl.edu
 Eric Leuthardt, MDPrincipal Investigator
North Carolina
  Winston-Salem
 Wake Forest University Comprehensive Cancer Center
 Wendy Jenkins, RN Ph: 336-716-3842
  Email: wejenkin@wakehealth.edu
 Stephen Tatter, MDPrincipal Investigator
Ohio
  Cleveland
 Cleveland Clinic Taussig Cancer Center
 Alireza Mohammadi, MD
  Email: MOHAMMA3@ccf.org
 Alizera Mohammadi, MDPrincipal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01651078
ClinicalTrials.gov processed this data on October 15, 2014

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top